New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novavax, Inc.

NVAX

Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.

Revenue
−3.05%
EPS
n/m
Free cash flow
n/m
Total debt
+19.3%

Quarter to September 2026, against a year earlier

7.74 0.01 +0.13%
Market cap
$1.3B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
−1.0×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters. ROE, at 41.1%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−117.2%79.7%323.7%41.1%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 11.64× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA−25.8×40.2×8.2×11.6×

Cash cycle, in days

Customers pay in 44 days, inventory is held 75 days and suppliers are paid in 101. Cash is tied up for 18 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle−31−5−3718
Days to pay suppliers1236695101
Days to be paid35141744

Per share, from Q4 FY25

Since Q4 FY25, per share: revenue has fallen 64.0%.

Revenue
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue1.0×0.5×0.4×0.4×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 1 1 0
ROE
(117.16%) 79.70% 323.66% 41.08%
ROA
32.17% (7.52%) (21.62%) (7.42%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
78.19% (15.96%) (51.76%) (18.52%)
Average Days of Receivables
34.58 14.27 16.53 43.59
Free Cash Flow per Share
(1.56) (0.59) (0.26) (1.47)
Free Cash Flow
(252.05) (96.79) (42.20) (243.25)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026